Form 8-K REGENERON PHARMACEUTICAL For: Aug 04

Go back to Form 8-K REGENERON PHARMACEUTICAL For: Aug 04

Roth Keeps Regeneron (REGN) at 'Buy' Following Q2 Report; Says 'Blocking and Tackling' Continues

August 4, 2016 2:55 PM EDT

Roth Capital affirms Regeneron (Nasdaq: REGN) with a Buy rating and $520 price target following Q2 results and updated guidance, as reported... More